Ubs Group Ag Tiziana Life Sciences LTD Call Options Transaction History
Ubs Group Ag
- $555 Billion
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding TLSA
# of Institutions
34Shares Held
4.61MCall Options Held
0Put Options Held
0-
Dauntless Investment Group, LLC Commerce Township, MI3.42MShares$6.97 Million9.57% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il199KShares$405,9390.0% of portfolio
-
Hsbc Holdings PLC London, X0105KShares$214,9440.0% of portfolio
-
Zhang Financial LLC89.8KShares$183,1100.01% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA86.1KShares$175,6130.0% of portfolio
About Tiziana Life Sciences Ltd
- Ticker TLSA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,273,000
- Market Cap $209M
- Description
- Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, m...